International Stem Cell (OTCMKTS:ISCO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

International Stem Cell Corp. (OTCMKTS:ISCOGet Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.15 and traded as high as $0.1850. International Stem Cell shares last traded at $0.17, with a volume of 501 shares.

International Stem Cell Stock Performance

The company has a market cap of $1.36 million, a price-to-earnings ratio of -2.83 and a beta of 0.06. The business has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.15.

International Stem Cell (OTCMKTS:ISCOGet Free Report) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The company had revenue of $2.32 million during the quarter.

About International Stem Cell

(Get Free Report)

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.

Read More

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.